Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates

Oncologist

Volumn 13, Issue 7, 2008, Pages 821-827

  Wang Gillam, Andrea ^a   Miles, Dorothy A ^b   Hutchins, Laura F ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

25 hydroxyvitamin D; Bisphosphonates; Breast cancer; Hyperparathyroidism; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ADULT; AGED; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER PATIENT; CLINICAL EVALUATION; DATA BASE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OSTEOPOROSIS; OUTPATIENT; PARATHYROID HORMONE BLOOD LEVEL; PHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SUPPLEMENTATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; RETROSPECTIVE STUDIES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 48749105616     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0013     Document Type: Review

References (29)

1. Zittermann A. Vitamin D in preventive medicine: Are we ignoring the evidence? Br J Nutr 2003;89:552-572.
2. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 2001;41:421-442.
3. John EM, Schwartz GG, Dreon DM et al. Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999;8:399-406.
4. Bertone-Johnson ER, Chen WY, Holick MF et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-1997.
5. Shin MH, Holmes MD, Hankinson SE et al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002;94:1301-1311.
6. Abbas S, Linseisen J, Slanger T et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study. Carcinogenesis 2008;29:93-99.
7. Ahonen MH, Tenkanen L, Teppo L et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-852.
8. Mordan-McCombs S, Valrance M, Zinser G et al. Calcium, vitamin D and the vitamin D receptor: Impact on prostate and breast cancer in preclinical models. Nutr Rev 2007;65:S131-S133.
9. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: A global perspective of current status. J Nutr 2005;135:310-316.
10. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-783.
11. Gloth FM 3rd, Gundberg CM, Hollis BW et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995;274:1683-1686.
12. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
13. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469.
14. Schussheim DH, Jacobs TP, Silverberg SJ. Hypocalcemia associated with alendronate. Ann Intern Med 1999;130:329.
15. Champallou C, Basuyau JP, Veyret C et al. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: Three clinical case reports. J Pain Symptom Manage 2003;25:185-190.
16. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003;348:1503-1504.
17. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004;328:335-336.
18. Breen TL, Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 2004;22:1531-1532.
19. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998;351:805-806.
20. Holick MF. Sunlight "D"ilemma: Risk of skin cancer or bone disease and muscle weakness. Lancet 2001;357:4-6.
21. Zadshir A, Tareen NP, Pan D et al. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis 2005;15(suppl 5):S5-97-S5-101.
22. Holick MF, Siris ES, Binkley N et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-3224.
23. Palmieri C, MacGregor T, Girgis S et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 2006;59:1334-1336.
24. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145-147.
25. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
26. Institute of Medicine, Food and Nutrition Board: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1999:250-286.
27. Johnson MA, Kimlin MG. Vitamin D, aging, and the 2005 Dietary Guidelines for Americans. Nutr Rev 2006;64:410-421.
28. Vieth R, Bischoff-Ferrari H, Boucher BJ et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 2007;85:649-650.
29. Allain TJ, Kirthisingha V, Beresford PA et al. Use of vitamin D supplements and vitamin D status in patients taking bisphosphonate drugs. Rheumatology (Oxford) 2006;45:486-487.